Does a UK R&D tax credit affect Form 5471?

Yes. A UK company's R&D tax credit changes its profit, corporation tax, and earnings and profits, and all three feed Form 5471. The merged RDEC credit flows through Schedule C, into current E&P on Schedule H, and on to the GILTI computation on Form 8992. Because the credit alters both income and the UK tax actually paid, it has to be reflected consistently across every linked schedule, not reported once and ignored.

Is the merged RDEC credit taxable income for US earnings and profits?

GOV.UK states the merged R&D expenditure credit is liable to Corporation Tax because it is classed as trading income, so it is an above-the-line credit that increases profit before tax. That higher profit carries into the US E&P calculation on Schedule H. A payable credit behaves differently, functioning as a cash claim or repayment rather than trading income, so the US preparer must first characterise which relief the UK company actually received.

How does a UK R&D credit affect the GILTI foreign tax credit?

The GILTI foreign tax credit is built on the UK corporation tax the company actually paid or accrued, net of the R&D credit, not on a gross figure. Because an R&D claim lowers the real UK tax cost, it reduces the deemed-paid foreign tax available to offset a GILTI inclusion computed on Form 8992. An individual owner without a section 962 election may face residual US tax that a gross-tax assumption would have concealed.

What is the difference between RDEC and a payable R&D credit for Form 5471?

The merged RDEC is an above-the-line credit that GOV.UK treats as taxable trading income, so it increases profit and the corporation tax charge, and it raises US earnings and profits as income. A payable credit, such as the one available under enhanced R&D intensive support, is a cash claim against HMRC. For Form 5471 the two are recorded in different places, and confusing them misstates both E&P and the creditable foreign tax.

Why do FRS 102 accounts need adjusting for a Form 5471 R&D claim?

FRS 102 lets a UK company capitalise qualifying development costs as an intangible asset, while US GAAP generally expenses research and development as incurred. Form 5471 Schedule C requires the income statement to be restated under US GAAP before it becomes E&P on Schedule H, so capitalised costs usually have to be unwound. The R&D credit sits on top of that conversion, so it must be recognised in the correct period to avoid double-counting the benefit.

Which Form 5471 schedules show a UK R&D tax credit?

A UK R&D credit appears across several schedules. Schedule C restates the income statement under US GAAP, Schedule H converts that income into current earnings and profits with the income taxes adjustment on line 2g, and Schedule E and Schedule E-1 track the UK corporation tax paid or accrued after the credit. Schedule I-1 then carries the tested income to Form 8992 for the US shareholder's GILTI calculation.

Form 5471 and a UK R&D Tax Credit: E&P and GILTI

Form 5471 is where a UK company's research and development (R&D) tax credit stops being a single line in a set of UK statutory accounts and becomes part of a US owner's controlled foreign corporation reporting. When a UK company claims the merged R&D expenditure credit (RDEC) or a payable R&D credit, that claim changes the company's profit, its corporation tax, and therefore its earnings and profits (E&P), which are the three things Form 5471 measures through Schedule C, Schedule H, and the global intangible low-taxed income (GILTI) computation. For a high-net-worth American founder who owns a UK company doing genuine R&D, the credit is good news for the business and a trap for the US return, because the way it is recognised under UK accounting rules is not the way it has to be reported for US tax.

How Does a UK R&D Tax Credit Reach Form 5471?

A UK R&D tax credit reaches Form 5471 through three linked schedules that build on each other. Schedule C restates the foreign corporation's income statement in its functional currency under US generally accepted accounting principles (GAAP). Schedule H, titled Current Earnings and Profits, then converts that income into current E&P under US standards. The tested income that falls out of the E&P figure feeds Schedule I-1, the schedule the IRS Instructions for Form 5471 describe as providing information relating to section 951A, and ultimately Form 8992, which the IRS titles U.S. Shareholder Calculation of Global Intangible Low-Taxed Income (GILTI). An R&D credit touches every stage of that chain: it changes the income on Schedule C, the E&P on Schedule H, the foreign tax available for credit, and the tested income that drives GILTI. Reporting it on one schedule and forgetting the knock-on effect on the next is where Form 5471 preparation for a UK R&D claimant goes wrong.

What Is the Difference Between the Merged RDEC Credit and a Payable R&D Credit?

The distinction matters for US tax because the two reliefs are recognised in completely different places in a set of accounts. GOV.UK states that the merged R&D expenditure credit scheme applies to accounting periods beginning on or after 1 April 2024, replacing the older RDEC and SME schemes, and that the rate of expenditure credit under the merged scheme is 20%. Critically for US purposes, GOV.UK is explicit that this expenditure credit is liable to Corporation Tax because it is classed as trading income. In other words, the merged RDEC is an above-the-line credit: it is recognised as a taxable receipt that increases the company's profit before tax, and is then itself taxed.

A payable credit behaves differently. GOV.UK describes enhanced R&D intensive support (ERIS) for loss-making, R&D-intensive small and medium enterprises that meet an intensity condition, giving an additional 86% deduction on qualifying costs on top of the existing 100% (a total of 186%) and a payable tax credit worth up to 14.5% of the surrenderable loss, which GOV.UK notes is not itself liable to tax. A payable credit is a cash claim against, or a repayment from, HM Revenue and Customs rather than extra trading income. For Form 5471, the US preparer has to characterise which of these the company actually received, because an above-the-line taxable receipt increases E&P as income, while a cash repayment of tax reduces the foreign tax that was paid.

How Does the Merged RDEC Credit Change a UK Company's Earnings and Profits?

Because the merged RDEC is brought into account as trading income, it raises the company's pre-tax profit in the UK accounts, and that higher profit is the starting point for the US E&P calculation. On Schedule C, the income statement is restated so that all information is reported in the foreign corporation's functional currency in accordance with US GAAP, and an above-the-line credit sits inside operating results rather than below the tax line. The practical effect is that the credit increases the income carried into Schedule H, and because GOV.UK confirms the credit is itself taxed, it also increases the corporation tax the company records for the year. The net cash benefit of the merged credit is therefore below the 20% headline rate, because the company pays corporation tax on the credit it receives. A US preparer who treats the full headline credit as a straight reduction of tax, rather than as taxable income that carries its own tax charge, will misstate both the income and the tax that Form 5471 depends on.

Where Does Schedule H Pick Up the R&D Credit?

Schedule H is the schedule that turns book income into US E&P, and it is where the R&D credit has to be reflected twice: once in the income figure and once in the tax figure. Schedule H starts from the current-year net income or loss per the foreign corporation's books and then applies a series of net additions and net subtractions on lines 2a through 2i to conform that result to US earnings and profits standards. The IRS Instructions direct that differences between the functional-currency income tax figure and the taxes that increase or reduce US E&P are accounted for on line 2g of Schedule H, the income taxes adjustment line. For a UK company with an R&D claim, line 2g is where the US treatment of the corporation tax, net of the credit, is reconciled against the figure sitting in the accounts. If the above-the-line credit has already lifted book income, the income side flows through line 1, while the tax side is adjusted on line 2g, and the two must be kept consistent so that E&P is neither overstated nor understated.

Schedule C: the R&D credit is restated into functional currency under US GAAP, with an above-the-line merged RDEC sitting in operating results and a payable credit treated according to its character
Schedule H, line 1: the credit-inflated net income per the foreign books is the starting point for current E&P
Schedule H, line 2g: the income taxes adjustment reconciles the UK corporation tax actually borne, net of the credit, to the amount that reduces US E&P
Schedule E and Schedule E-1: the UK corporation tax actually paid or accrued, after the credit, enters the foreign tax pool that later supports a credit on the US return
Schedule I-1 and Form 8992: the tested income that remains after the E&P adjustments feeds the US shareholder's GILTI calculation

Why Does the UK Tax Actually Paid, Net of the Credit, Drive the GILTI Foreign Tax Credit?

When a US owner has a GILTI inclusion from a UK company, the foreign tax credit that offsets it is built on the UK corporation tax the company actually paid or accrued, not on a gross figure before the R&D credit. An R&D credit reduces the real UK tax cost, so it reduces the foreign tax that is available to credit against the US GILTI charge. If the merged RDEC is recognised as taxable income, it raises the tax base and the tax on it; if a payable credit operates as a repayment of tax, it directly reduces the tax that was paid. Either way, the number that matters for the US foreign tax credit is the net UK tax the company genuinely bore after the claim.

This feeds directly into Form 8992. The GILTI regime allows a deemed-paid foreign tax credit for the taxes properly attributable to tested income, but only a portion of those tested foreign income taxes is creditable against a GILTI inclusion, and the inclusion is computed on Form 8992 using the tested income reported through Schedule I-1. A UK company that has reduced its effective corporation tax rate with an R&D claim may find the net UK tax is low enough that the deemed-paid credit no longer fully shelters the GILTI inclusion, leaving residual US tax, particularly for an individual shareholder who has not made a section 962 election to be taxed as a domestic corporation on that income. Treating the R&D credit as if it had no effect on creditable foreign tax is the fastest way to overstate the GILTI foreign tax credit and understate US tax due.

How Does Converting FRS 102 Accounts to US GAAP and E&P Affect the R&D Credit?

Most UK private companies prepare their statutory accounts under FRS 102, the UK and Ireland financial reporting standard, and those accounts are the raw material a US preparer must convert before anything reaches Schedule C. FRS 102 permits development expenditure that meets the recognition criteria to be capitalised as an intangible asset and amortised over its useful life, while research costs are expensed as incurred. US GAAP is generally stricter: under the long-standing research and development standard, most R&D costs are expensed as incurred, with only limited exceptions. A UK company that has capitalised development costs on its FRS 102 balance sheet therefore carries a book profit that US GAAP would not recognise in the same way, and that difference has to be unwound on Schedule C before the income statement is translated into E&P on Schedule H.

The R&D credit sits on top of that conversion. If development costs are capitalised under FRS 102, the merged RDEC claimed on that expenditure, and the timing of the income the credit represents, may not line up with the US GAAP expensing of the same costs. The US preparer has to make sure the credit is recognised in the right period and that it is not double-counted once the capitalised costs are expensed for US purposes. Getting the FRS 102 to US GAAP conversion wrong does not just misstate E&P in a single year; because Schedule H opening positions and the foreign tax pool carry forward, an error in the first year a credit is claimed propagates into every later Form 5471.

Capitalised development costs: FRS 102 may capitalise and amortise them, while US GAAP generally expenses R&D as incurred, so book profit has to be adjusted on Schedule C
Credit timing: the period in which the merged RDEC is recognised as income under UK accounting may differ from when the related costs are expensed for US purposes
Credit character: confirm whether the company took the above-the-line taxable merged RDEC or a payable credit, because each hits E&P and foreign tax differently
Functional currency: Schedule C reports in the company's functional currency, usually sterling, before any translation, so the credit must be captured in the right currency first
Carryforward integrity: a first-year conversion error in E&P and the foreign tax pool repeats on every subsequent Form 5471 until it is corrected

Worked Scenario: A UK Software Company Claiming the Merged RDEC Credit

Illustrative scenario, with assumed figures for illustration only. A US citizen wholly owns a profitable UK software company with a 31 December accounting period. The company has qualifying R&D expenditure and claims the merged RDEC at the 20% rate that GOV.UK sets for the scheme. Because GOV.UK confirms the credit is classed as trading income, the credit increases the company's profit before tax in its FRS 102 accounts, and the company pays corporation tax on that larger profit, so the net cash benefit it keeps is below the 20% headline. The company makes no distribution to its US owner in the year.

On the US side, the preparer first converts the FRS 102 accounts to US GAAP on Schedule C, reversing any development costs the company had capitalised so that they are expensed, and confirming the above-the-line credit is reflected in operating results in sterling. That restated income flows to Schedule H, line 1. On line 2g, the preparer reconciles the UK corporation tax the company actually bore, net of the merged credit, to the figure that reduces US E&P. The resulting tested income carries through Schedule I-1 to Form 8992. Because the R&D claim lowered the company's effective UK tax, the deemed-paid foreign tax credit attributable to the tested income is smaller than the gross corporation tax figure would suggest, and the individual owner, absent a section 962 election, may face residual US tax on the GILTI inclusion that a gross-tax assumption would have hidden.

What Errors Corrupt the Form 5471 Treatment of a UK R&D Credit?

Treating the merged RDEC as a straight reduction of corporation tax rather than as taxable trading income that increases both profit and the tax charge
Carrying FRS 102 capitalised development costs straight onto Schedule C without conforming them to US GAAP expensing
Using the gross UK corporation tax figure, before the R&D credit, to compute the GILTI foreign tax credit and overstating the credit as a result
Mixing up an above-the-line merged credit with a payable credit, so the receipt is recorded as income when it was a repayment of tax, or the reverse
Recognising the credit in a different period for US purposes than the related costs are expensed, double-counting the benefit across years
Letting a first-year E&P or foreign tax pool error carry forward into every subsequent Form 5471 without reconciling the opening balances

How US-UK Tax Prepares Form 5471 for UK Companies Claiming R&D Credits

Preparing Form 5471 for a UK company with an R&D claim starts with the accounts, not the form. We identify whether the company took the above-the-line merged RDEC that GOV.UK treats as taxable trading income or a payable credit, convert the FRS 102 statutory accounts to US GAAP on Schedule C, and reconcile the result into current E&P on Schedule H, with the UK corporation tax actually borne, net of the credit, reflected on the income taxes adjustment line. From there we carry the tested income through Schedule I-1 to the GILTI calculation on Form 8992 and confirm that the deemed-paid foreign tax credit reflects the real, post-credit UK tax rather than a gross figure. For a high-net-worth American who owns a UK company doing genuine research and development, the R&D credit should reduce UK tax without creating an unexpected US liability or an inaccurate Form 5471. We prepare the controlled foreign corporation reporting, the E&P conversion, and the GILTI computation together, so the UK claim and the US return tell a consistent story.